Virtual Care AI Provider Expands Potential Access to 100k+ New York Covered Lives

1. Rocket Doctor is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
2. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor
3. Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
4.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1 Disclosure for the quote from the Stewart Thomson article published on March 17, 2026

1. For the quoted article (published on March 17, Rocket Doctor has paid Street Smart, an affiliate of Streetwise Reports, US$2,500
2. Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts.  The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Rocket Doctor AI Inc.'s (AIDR:CSE; AIRDF:OTC; 939:FRA) recent payer agreement highlights growing demand for scalable virtual care solutions that integrate licensed physicians with digital platforms. The digital health sector continues to attract attention from retail investors seeking exposure to companies that combine technology with established reimbursement pathways.

The broader healthcare technology market faces pressure from aging populations and rising chronic disease rates, yet benefits from tools that extend access beyond traditional clinic walls. Rocket Doctor AI stands out because its platform already connects patients to in-network physicians across multiple states while building AI features designed specifically for clinical workflows.

Why Rocket Doctor AI Stands Out in Digital Health

Under the agreement, Rocket Doctor is now accessible to more than 100,000 additional eligible lives across participating individual Medicare Advantage PPO and commercial health plans in the New York metropolitan region and select upstate counties. The estimate excludes millions of members covered through administrative services only or self-insured plans. The payer also participates in a national reciprocal network program, allowing eligible out-of-state members to access Rocket Doctor's in-network physicians while traveling in New York.

With the latest agreement, Rocket Doctor reports potential in-network access to approximately 10 million covered lives in New York and approximately 24 million covered lives nationwide through its commercial and public payer relationships. These figures represent potential access to people covered by participating plans, not the company's current patient population. The agreement was signed on July 15 and has an initial one-year term, with automatic one-year renewals unless terminated or non-renewed by either party in accordance with its terms.

Key Investor Takeaways

• “Rocket Doctor AI secured in-network access to more than 100,000 additional eligible New York covered lives through a new payer agreement signed July 15.
• The company reports potential in-network access to roughly 10 million covered lives in New York and 24 million nationwide through its payer relationships.
• Physician numbers continue to grow, with 22 clinically active US doctors and 33 more in credentialing as of the August investor overview.
• US patient visits rose steadily from 86 in December 2025 to 1,144 in April, showing operational traction.
• Technical analyst Stewart Thomson assigned a Strong Speculative Buy rating with price targets of CA$0.80 short term CA$1.00 medium term and CA$1.60 long term.¹
• Expansion plans target Florida and Texas while extending current payer contracts across Medicaid, Medicare Advantage, and commercial channels.

Unique Business Model and AI Advantages

Rocket Doctor recently announced expanded in-network access to physician-led virtual care in New York through a new agreement entered into by doctors using its digital health platform and marketplace.

Rocket Doctor's programs allow patients to connect with licensed physicians from home for services including urgent care, chronic disease management, preventive health, pediatrics, and mental health support. Eligible members can access the services through their existing insurance coverage under Rocket Doctor's in-network participation. 

"This agreement represents another important milestone in our strategy to expand reimbursed access to physician-led care," said Dr. William Cherniak, co-founder and chief executive officer of Rocket Doctor. "By increasing the number of patients who can connect with physicians through their existing health benefits, we are helping reduce financial barriers to care while building a more sustainable model for delivering high-quality virtual care at scale."

Industry Timing and Broader Digital Health Trends

The World Bank Group's Paschal Donohoe wrote on August 3 that healthcare systems globally had been facing pressure from aging populations, rising chronic disease, and growing demand for specialized care, while geography continued to affect access to timely care. He described digital technology as a way to extend healthcare services when it was "well-designed, governed responsibly, and embedded in broader health-system reform."

Donohoe pointed to virtual healthcare programs that had combined medical expertise with digital technologies to provide remote services, including virtual critical care, specialty consultations, and home-care services. He wrote that "digital technology can improve patient care" by extending expertise beyond hospital walls.

At the same time, Donohoe cautioned that technology was not a substitute for the broader healthcare system. "Virtual care is not a shortcut to deeper healthcare reforms," he wrote. "It cannot replace skilled providers, systems, or patient trust." He said digital healthcare raised legal and regulatory questions and that countries needed to determine which services were clinically effective and which training approaches best helped workers serve patients.

A report distributed through EIN Presswire on August 10 said U.S. healthcare and pharmaceutical marketers were expected to spend US$26.15 billion on digital advertising during 2026, representing a 5.6% year-over-year increase, according to eMarketer. The report also said 2025 marked the first year that social media spending exceeded linear television spending in the category.

In an August 11 article, Gilda D'Incerti examined healthcare AI adoption through the industry's previous experiences with electronic health records, revenue-cycle modernization, telehealth expansion, and other digital transformations. She wrote that healthcare's experience had shown that technological implementation depended on organizational factors, including workflow redesign, clinician acceptance, and training.

Analyst Views and Technical Outlook

¹Technical analyst Stewart Thomson gave Rocket Doctor AI Inc. a Strong Speculative Buy technical rating in a March 17 report, citing the company's healthcare technology, U.S. payer relationships, and physician-oriented platform.

Thomson described Rocket Doctor's technology as being developed around the needs of healthcare providers. He wrote that the company's AI platform "is designed by doctors, so doctors who use it get exactly what they need," and said its approach was "centered on enhancing provider capabilities, not replacing clinical decisions." He also cited smart triage and matching technology, remote patient monitoring, multilingual care, and support for multiple medical specialties.

The analyst also discussed Rocket Doctor's expansion in the United States. He cited an in-network agreement in New York that he said increased the company's nationwide reach to more than 15 million members. Thomson also referenced a US$1 million Healthy Aging Program grant launched with CVS Health Foundation, through a partnership the Company announced with Engagewell on July 10, 2025.

Thomson established three technical price targets for the shares: CA$0.80 in the short term, CA$1.00 in the medium term, and CA$1.60 in the long term.

Key Assets, Projects, and Ongoing Catalysts

Rocket Doctor AI's August investor overview identified additional state expansion, physician credentialing, and development of its healthcare AI products among the company's ongoing programs.

The presentation identified Florida and Texas among the company's state expansion pipeline and listed its strategy as extending existing relationships with payers. At the time reflected in the presentation, Rocket Doctor listed 9,875,993 covered lives with potential in-network access in New York, 8,126,637 in California, and 3,180,599 in Maryland.

The company's U.S. payer approach covers channels including: Medicaid and Medicaid Managed Care, Medicare and Medicare Advantage, HR and employer benefits, commercial insurance, and out-of-network patients. The presentation stated that each payer relationship could provide indicative potential access to 1 million to 2 million or more covered lives.

Physician credentialing represents another ongoing work stream. The presentation reported 22 clinically active U.S. physicians and another 33 physicians in credentialing. It also listed pending physician capacity at three times the number of clinically active U.S. physicians.

Rocket Doctor AI also described a connected suite of healthcare AI solutions encompassing its digital health platform and marketplace, AI Assistants, Electronic Medical Records (EMR), access to Bluetooth-enabled medical devices, AI Scribe, the Global Library of Medicine (GLM), and billing and revenue reconciliation.

The company's AI-supported care workflow covers intake, patient visits, and follow-up. Intake features listed in the presentation include symptom-based smart intake, doctor and patient matching, auto-booking, initial care assessments, and an AI agent. Patient-visit functions include AI-driven diagnostic support, questioning through chat and video, appointments, referrals, labs and imaging, and real-time updates to the patient chart. Follow-up functions include chronic-condition management, future appointments and reminders, preset follow-ups, and an AI agent.

Rocket Doctor AI's Global Library of Medicine (GLM) has been in development since 2016, with more than 25,000 hours of input from hundreds of clinicians globally and approximately 10,000 or more expert medical reviews. The GLM includes more than 1,000 diseases and 17,000 symptoms in real time and suggests appropriate lab tests and imaging, treatment options, and billing codes. The company also described plug-and-play API integration for connecting the system to other platforms, such as EMRs, AI Scribes, and/or other healthcare systems offering patient-facing services.

The presentation also identifies continued physician and patient activity and growth in the United States. Total completed U.S. patient visits increased from 86 in December 2025 to 177 in January, 464 in February, 678 in March, and 1,144 in April. U.S. clinical hours increased from 75 in December to 110 in January, 434 in February, 577 in March, and 624 in April.

Share Structure and Market Position

As of August 13, 2026, Insider ownership of Rocket Doctor AI totals 4.24%. Retail investors hold the rest.²

As of August 13, 2026, Rocket Doctor AI has approximately 101.03 million shares outstanding. Its market capitalization is approximately CA$59.61 million, and its 52-week trading range is CA$0.47 to CA$0.98 per share.

Common Questions from Investors

How many additional covered lives did the latest New York agreement add?

The agreement provides in-network access for more than 100,000 additional eligible lives across Medicare Advantage PPO and commercial plans in the New York region and select upstate counties.

What is Rocket Doctor AI's current potential reach across New York and the United States?

Following the agreement, the company reports potential in-network access to approximately 10 million covered lives in New York and 24 million nationwide.

Which states are targeted for further expansion?

The August investor overview lists Florida and Texas in the state expansion pipeline while focusing on extending existing payer relationships.

What growth has been reported in US patient visits?

Completed US patient visits rose from 86 in December 2025 to 1144 in April, according to the investor overview.

What price targets did analyst Stewart Thomson set?

Thomson set technical targets of CA$0.80 short-term, CA$1.00 medium-term, and CA$1.60 long-term.

Retail investors evaluating Rocket Doctor AI should consider both the expanding payer footprint and the need for continued physician credentialing and revenue growth to support long-term sustainability.